Anthracycline Coordination Chemistry: DOX-Fe Complexation and Mitochondrial Sequestration
Doxorubicin-mediated cardiotoxicity relies on coordination chemistry occurring between the anthracycline aglycone core and transition metal ions [1]. Doxorubicin coordinates iron through adjacent quinone and phenolic oxygen atoms located at the C11 and C12 positions, generating pseudobidentate complexes with distinct stoichiometric geometries [1][2]. In the presence of ferric iron, a 3:1 DOX-Fe³⁺ coordination species forms spontaneously, which subsequently undergoes intramolecular electron transfer to yield active DOX-Fe²⁺ complexes [1]. These coordinate arrangements alter the reduction-oxidation potential of the bound transition metal, accelerating electron transfer to molecular oxygen [1]. Cardiomyocytes are uniquely vulnerable to this chemistry due to the rapid accumulation of the drug inside cardiac mitochondria [2][3]. Driven by an electrostatic affinity for negatively charged diphosphatidylglycerol (cardiolipin; association constant Ka ≈ 1.6 × 10[6] M^-1), doxorubicin concentrates across the inner mitochondrial membrane up to 1,000-fold relative to cytosolic levels [1][3]. Table 1 benchmarks the specific biochemical, affinity, and pharmacokinetic metrics defining this targeted organellar distribution against common cardioprotective chemical probes.
This physical partitioning is exacerbated by direct anthracycline-dependent disruptions of mitochondrial iron export machinery [2]. Exposure of H9C2 rat cardiomyoblasts to doxorubicin downregulates ATP-binding cassette sub-family B member 8 (ABCB8), an inner membrane transporter responsible for facilitating iron translocation from the matrix to the cytosol [2][3]. Concomitantly, the expression of mitoferrin is perturbed while iron-regulatory proteins (IRPs) are activated, promoting unrestrained entry of ionic iron into the mitochondrial matrix [2][3]. The resulting accumulation of labile Fe²⁺ within the inner cristae provides the necessary catalytic substrate for localized, site-specific Fenton cascades [1][2].
Respiratory Complex I Redox Cycling and Hydroxyl Radical Generation via Fenton Cascades
Once integrated into the mitochondrial inner membrane architecture, the quinone moiety of doxorubicin serves as an artificial electron acceptor for the respiratory chain [1][4]. Mitochondrial NADH dehydrogenase (Complex I) catalyzes the univalent reduction of the anthracycline quinone into an unstable semiquinone radical intermediate [1]. Endothelial nitric oxide synthase (eNOS) and mitochondrial NADPH oxidases can additionally mediate this single-electron transfer [1]. Under normoxic conditions, the semiquinone intermediate rapidly transfers its unpaired electron to ground-state molecular oxygen, regenerating the parent quinone backbone while generating sustained fluxes of superoxide anion radicals (O₂^{\bullet-}) within the matrix space [1][4].
Matrix-localized manganese superoxide dismutase (MnSOD/SOD2) disproportionates O₂^{\bullet-} into hydrogen peroxide (H₂O₂) [1]. In unperturbed cardiomyocytes, mitochondrial peroxiredoxins and glutathione peroxidases eliminate this intermediate; however, in the presence of the localized DOX-Fe²⁺ coordination complex, H₂O₂ participates in accelerated Fenton chemistry [1][2]. The complexed divalent iron catalyzes the homolytic cleavage of the oxygen-oxygen single bond in H₂O₂, generating reactive hydroxyl radicals (^{\bulletOH}) and ferryl ion intermediates [1]. In HL-1 murine cardiomyocytes, this localized radical burst evades cytosolic enzymatic antioxidants [5]. The generated ^{\bulletOH} radicals display a diffusion radius under 5 nm, focusing oxidative damage directly onto adjacent inner membrane protein complexes and polyunsaturated fatty acid (PUFA) tails [4][5].
Cardiolipin Oxidation Signatures and Inner Membrane Lipid Peroxidation
The catastrophic collapse of cardiomyocyte integrity during anthracycline treatment stems from uncontrolled free radical lipid autoxidation rather than stochastic cytosolic proteolysis [1][5]. Because doxorubicin remains electrostatically anchored to cardiolipin, the localized flux of ^{\bulletOH} selectively abstracts bis-allylic hydrogen atoms from polyunsaturated acyl side chains [1]. Inner mitochondrial membranes maintain high concentrations of tetralinoleoyl cardiolipin (TLCL), a unique phospholipid containing four linoleic acid chains (18:2 cis-9,12) [1]. Hydrogen abstraction at carbon-11 of these linoleoyl moieties creates carbon-centered pentadienyl radicals, which react with molecular oxygen to generate lipid peroxyl radicals (LOO•) [1][5].
This peroxidation process is coordinated by acyl-CoA synthetase long-chain family member 4 (ACSL4) and lysophosphatidylcholine acyltransferase 3 (LPCAT3), which esterify polyunsaturated fatty acids into membrane phosphatidylethanolamines (PE) [1][6]. In H9C2 cardiomyocytes, doxorubicin exposure upregulates ACSL4 expression, altering membrane fluidity and increasing the abundance of arachidonoyl (AA) and adrenoyl (AdA) lipid species [1][6]. Propagation of the radical chain reaction drives oxidative cleavage of cardiolipin and PE species, yielding reactive bifunctional electrophiles, including 4-hydroxynonenal (4-HNE) and malondialdehyde (MDA) [1][6]. Assays utilizing the lipophilic fluorescent probe C11-BODIPY (581/591) demonstrate rapid oxidation of cardiomyocyte membranes within 16 to 24 hours of exposure [5][6]. The accumulation of oxidized cardiolipin disrupts respiratory supercomplex stability, triggers inner membrane permeabilization, dissipates mitochondrial membrane potential (ΔΨm), and halts ATP synthesis [1][5].
Suppression of the System Xc-/GPX4 Axis and Mitochondrial Glutathione Depletion
Cardiomyocytes resist ferroptotic death through glutathione peroxidase 4 (GPX4), an enzymatic scavenger that directly reduces toxic phospholipid hydroperoxides (PLOOH) to non-reactive lipid alcohols (PLOH) utilizing reduced glutathione (GSH) [1][3]. Doxorubicin treatment dismantles this primary defense system across transcriptional, translational, and post-translational tiers [3][6]. Doxorubicin promotes the transcriptional downregulation of solute carrier family 7 member 11 (SLC7A11), the catalytic light chain of the cystine/glutamate antiporter System Xc- [6]. The subsequent deprivation of intracellular L-cysteine arrests de novo glutathione biosynthesis, depleting total cellular GSH as well as the independent mitochondrial GSH (mtGSH) pool [3][6].
Concurrently, doxorubicin treatment triggers rapid clearance of GPX4 protein via accelerated chaperone-mediated autophagy (CMA) and ubiquitin-proteasome degradation pathways [3][7]. Depletion of GPX4 abolishes the primary biochemical barrier against cardiolipin and PE hydroperoxide propagation [1][7]. Because mitochondria lack functional ferroptosis suppressor protein 1 (FSP1)-dependent ubiquinone recycling cascades along the inner cristae, the organelle remains devoid of back-up radical-trapping defenses [1][7]. The resulting unrestrained PLOOH amplification drives irreversible membrane rupture, uncoupling oxidative phosphorylation and releasing metabolic intermediates that signal ferroptotic execution [3][7].
Pharmacological Mitigation: Iron Chelation and Radical-Trapping Countermeasures
The therapeutic distinction of ferroptosis from apoptosis or necroptosis in anthracycline cardiotoxicity is substantiated by distinct pharmacological rescue profiles [5][7]. In primary cultures of neonatal rat cardiomyocytes (NRCMs) and human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), cell death induced by 0.5 to 2.0 μM doxorubicin remains entirely insensitive to the pan-caspase inhibitor Z-VAD-FMK and the receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor necrostatin-1 [7][8]. Conversely, intervention with lipophilic radical-trapping antioxidants (RTAs) or targeted iron chelators confers robust protection against membrane destruction [5][7].
Dexrazoxane (ICRF-187), an established clinical cardioprotectant, undergoes intracellular hydrolysis into its active diacid diamide metabolite, ADR-925 [1]. ADR-925 directly binds and removes iron from the preformed DOX-Fe³⁺ complex, neutralizing its ability to cycle electrons or drive localized Fenton chemistry [1]. Similarly, lipophilic RTAs, such as ferrostatin-1 (Fer-1) and liproxstatin-1 (Lip-1), intercept propagating lipid peroxyl radicals by donating hydrogen atoms at rates faster than auto-oxidation propagation, halting cardiolipin cleavage [5][7]. Mitochondria-targeted scavengers, such as MitoTEMPO, selectively suppress mitochondrial reactive oxygen species, restoring TOM20 levels and preservation of membrane structural integrity in HL-1 cells [5]. These empirical outcomes demonstrate that ferroptotic lipid autoxidation localized to mitochondrial membranes represents the primary pathway driving acute anthracycline cardiomyopathy, revealing precision interventional nodes capable of shielding the myocardium during oncology regimens [1][5][7].